ロード中...
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been imp...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5955151/ https://ncbi.nlm.nih.gov/pubmed/29774105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25072 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|